Scientific Reports (Oct 2024)
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
- Neslihan Özyurt,
- Ali Alkan,
- Burcu Gülbağcı,
- Mustafa Seyyar,
- Esra Aydın,
- Mustafa Şahbazlar,
- Mehmet Türker,
- Oğuzcan Kınıkoğlu,
- Tahir Yerlikaya,
- Gülhan Dinç,
- Ali Aytaç,
- Ziya Kalkan,
- Senar Ebinç,
- İlkay Gültürk,
- Merve Keskinkılıç,
- Zehra Sucuoğlu İşleyen,
- Dilek Çağlayan,
- Alper Türkel,
- Esra Aydın,
- Teoman Şakalar,
- Serhat Sekmek,
- Nilgün Yıldırım,
- Sinem Koçak,
- Kerem Okutur,
- Ahmet Özveren,
- Bengü Dursun,
- Sait Kitaplı,
- Orhan Önder Eren,
- İsmail Beypınar,
- İlhan Hacıbekiroğlu,
- Devrim Çabuk,
- Elanur Karaman,
- Ömer Acar,
- Semra Paydaş,
- Melek Karakurt Eryılmaz,
- Bilgin Demir,
- Zeynep Oruç,
- Mesut Yılmaz,
- Fatih Selçuk Biricik,
- Derya Kıvrak Salim,
- Özgür Tanrıverdi,
- Mutlu Doğan
Affiliations
- Neslihan Özyurt
- Department of Medical Oncology, Ordu University School of Medicine
- Ali Alkan
- Department of Medical Oncology, Muğla Sıtkı Koçman University School of Medicine
- Burcu Gülbağcı
- Department of Medical Oncology, Sakarya University School of Medicine
- Mustafa Seyyar
- Department of Medical Oncology, Kocaeli University School of Medicine
- Esra Aydın
- Department of Medical Oncology, Karadeniz Technical University School of Medicine
- Mustafa Şahbazlar
- Department of Medical Oncology, Celal Bayar University School of Medicine
- Mehmet Türker
- Department of Medical Oncology, Çukurova University School of Medicine
- Oğuzcan Kınıkoğlu
- Department of Medical Oncology, Kartal Training and Research Hospital
- Tahir Yerlikaya
- Department of Medical Oncology, Antalya Training and Research Hospital
- Gülhan Dinç
- Department of Medical Oncology, Okmeydanı Training and Research Hospital
- Ali Aytaç
- Department of Medical Oncology, Aydın Adnan Menderes University School of Medicine
- Ziya Kalkan
- Department of Medical Oncology, Dicle University School of Medicine
- Senar Ebinç
- Diyarbakır Training and Research Hospital, Department of Medical Oncology
- İlkay Gültürk
- Department of Medical Oncology, Bakırköy Sadi Konuk Training and Research Hospital
- Merve Keskinkılıç
- Department of Medical Oncology, Dokuz Eylül University School of Medicine
- Zehra Sucuoğlu İşleyen
- Department of Medical Oncology, Bezm-i Alem Vakıf University School of Medicine
- Dilek Çağlayan
- Department of Medical Oncology, Necmettin Erbakan University School of Medicine
- Alper Türkel
- Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
- Esra Aydın
- Department of Medical Oncology, Recep Tayyip Erdoğan University School of Medicine
- Teoman Şakalar
- Department of Medical Oncology, Kahramanmaraş Necip Fazıl City Hospital
- Serhat Sekmek
- Ankara Bilkent City Hospital, Department of Medical Oncology
- Nilgün Yıldırım
- Department of Medical Oncology, Fırat University School of Medicine
- Sinem Koçak
- Department of Medical Oncology, Koç University School of Medicine
- Kerem Okutur
- Department of Medical Oncology, İstanbul Arel University School of Medicine
- Ahmet Özveren
- Department of Medical Oncology, Acıbadem Kent Hospital
- Bengü Dursun
- Department of Medical Oncology, Ankara University School of Medicine
- Sait Kitaplı
- Department of Medical Oncology, Muğla Sıtkı Koçman University School of Medicine
- Orhan Önder Eren
- Department of Medical Oncology, Selçuk University School of Medicine
- İsmail Beypınar
- Department of Medical Oncology, Alanya Alaittin Keykubat University School of Medicine
- İlhan Hacıbekiroğlu
- Department of Medical Oncology, Sakarya University School of Medicine
- Devrim Çabuk
- Department of Medical Oncology, Kocaeli University School of Medicine
- Elanur Karaman
- Department of Medical Oncology, Karadeniz Technical University School of Medicine
- Ömer Acar
- Department of Medical Oncology, Celal Bayar University School of Medicine
- Semra Paydaş
- Department of Medical Oncology, Çukurova University School of Medicine
- Melek Karakurt Eryılmaz
- Department of Medical Oncology, Necmettin Erbakan University School of Medicine
- Bilgin Demir
- Department of Medical Oncology, Aydın Adnan Menderes University School of Medicine
- Zeynep Oruç
- Department of Medical Oncology, Dicle University School of Medicine
- Mesut Yılmaz
- Department of Medical Oncology, Bakırköy Sadi Konuk Training and Research Hospital
- Fatih Selçuk Biricik
- Department of Medical Oncology, Koç University School of Medicine
- Derya Kıvrak Salim
- Department of Medical Oncology, Antalya Training and Research Hospital
- Özgür Tanrıverdi
- Department of Medical Oncology, Muğla Sıtkı Koçman University School of Medicine
- Mutlu Doğan
- Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
- DOI
- https://doi.org/10.1038/s41598-024-75293-5
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 12
Abstract
Abstract The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis; presence of LVI (HR:2.2 (95% CI 1.1–3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2–0.6) p < 0.001) and lymph node negativity (HR:0.35 (95% CI 0.1–0.9) p = 0.03) were independent factors for OS. Although there were pathological and clinical differences, the pCR, DFS and OS were similar between Her2-0 and Her2-low TNBC patients. The importance of Her2 status of TNBC in neoadjuvant setting should be further studied.
